Clinical Trials Logo

Filter by:
NCT ID: NCT03894046 Completed - Bacteremia Clinical Trials

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

ATTACK
Start date: September 5, 2019
Phase: Phase 3
Study type: Interventional

This is a 2-part study, with Part A being the randomized, controlled portion of the study in patients with ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to or have failed colistin or polymyxin B treatment, as detailed in the inclusion criteria.

NCT ID: NCT03892421 Completed - Clinical trials for Refractory Non-Hodgkin Lymphoma

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

Start date: April 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to evaluate the efficacy and safety of a combination of the anti-CD20 monoclonal antibody Rituximab, Dexamethasone, daily high dose Cytarabine twice, and Carboplatin; delivered in an outpatient setting.

NCT ID: NCT03888976 Completed - Clinical trials for Gallbladder Diseases

Cholecystoduodenal Fistula With and Without Gallstone Ileus

Start date: February 1, 2019
Phase:
Study type: Observational

Observative and descriptive study of 10 patients, which were diagnosed with a Cholecystoduodenal fistula, All electronic medical records were retrospectively reviewed.

NCT ID: NCT03888066 Completed - Hyperkalemia Clinical Trials

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

DIAMOND
Start date: April 24, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.

NCT ID: NCT03887520 Completed - Clinical trials for Cardiovascular Disease and Lipoprotein(a)

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Start date: November 27, 2018
Phase: N/A
Study type: Interventional

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

NCT ID: NCT03884010 Completed - Body Composition Clinical Trials

Accuracy of Anthropometric Equations to Estimate DXA-Derived Skeletal Muscle Mass in Professional Male Soccer Players

Start date: August 2009
Phase:
Study type: Observational

This study aimed to analyze the accuracy of different anthropometric equations to estimate skeletal muscle mass in professional male soccer players, setting dual-energy x-ray absorptiometry (DXA) skeletal muscle mass as the reference.

NCT ID: NCT03883997 Completed - Body Composition Clinical Trials

Accuracy of Anthropometric Equations for Estimating Body Fat in Professional Male Soccer Players Compared With DXA

Start date: August 2009
Phase:
Study type: Observational

This study aimed to analyze the accuracy of different anthropometric equations to estimate body fat in professional male soccer players, setting DXA body fat as the reference.

NCT ID: NCT03877120 Completed - Clinical trials for Alcohol Withdrawal Delirium

Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán

Start date: November 1, 2017
Phase: Phase 4
Study type: Interventional

The cessation of alcohol consumption of people suffering from alcohol abuse frequently leads to the development of an alcohol withdrawal syndrome (AWS). The ethylic suppression syndrome is defined as the appearance of two or more data of autonomic hyperactivity, nausea, hallucinations and seizures associated with the cessation of alcohol consumption. For its evaluation, the CIWA-Ar scale is used, which guides the treatment based on benzodiazepines but with many adverse effects, so sedatives have been tried, among them dexmedetomidine, an alpha-agonist with action in the locus caeruleus, with variable results. Objectives: The investigators aimed to compare the DEX vs. Diazepam, for moderate disease, applying the CIWA-Ar scale, in participants with severe to moderate AWS. Methodology: 40 participants with CIWA-Ar greater than 10 points, the investigators are collected and randomized into two groups: one under treatment with diazepam (Group Diazepam) and another with dexmedetomidine (Group Dexmedetomidine), until the CIWA-Ar was reduced to less than 10, and adverse effects the investigators also reported. The analysis was done with student t. Results: The average duration of treatment with diazepam was 5.5 days (IC 95 = 6.6-3.8), the average duration of treatment with dexmedetomidine was 3.1 days (95% CI = 4.5-1.7), with a significant difference ( p = 0.0016). In the group with diazepam 60% presented adverse effects and in the group with dexmedetomidine 25% presented them, with a significant difference (p = 0.04). Conclusion: dexmedetomidine was superior to diazepam for the treatment of moderate-severe alcohol withdrawal with fewer adverse effects. KEY WORDS: Alcohol dependence · Alcohol withdrawal syndrome · Dexmedetomidine · Diazepam · Benzodiazepines

NCT ID: NCT03873246 Completed - Dry Eye Disease Clinical Trials

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Start date: February 18, 2019
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the chronic safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs of dry eye disease (DED).

NCT ID: NCT03871582 Completed - Aging Clinical Trials

Number of Meals With Adequate Protein Intake and Functionality in Middle to Older Aged Mexican Adults

Start date: January 2017
Phase:
Study type: Observational

The objective of this study was to analyze if the number of meals with adequate protein intake is associated with functionality in middle to older aged mexican adults.